Skip to main content

Triamcinolone Acetonide Intravitreal Injection Shortage

Last Updated: October 26, 2024
Status: Current

Reason for the Shortage
    • Novartis divested Triesence to Harrow Eye, LLC in late-November 2023.
    • Harrow Eye, LLC had Triesence on shortage due to manufacturing delays related to good manufacturing practices.
    • They are the sole suppliers.
Available Products
    • Triesence intravitreal suspension for injection, Harrow Eye, LLC, 40 mg/mL, 1 mL vial, NDC 00065-0543-01

Estimated Resupply Dates

    • Harrow Eye, LLC has Triesence 40 mg/mL 1 mL vials available.

Updated

Updated October 26, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 30, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.